NASDAQ:SLRX   Salarius Pharmaceuticals, Inc.
Hello,

What is SLRX?
Salarius Pharmaceuticals, Inc. a clinical-stage biotechnology company, develops epigenetic-based cancer treatments. The company's lead candidate is Seclidemstat (SP-2577), which is in Phase I/II clinical trial for the treatment of advanced solid tumors, including prostate, breast, and ovarian cancers, as well as Ewing sarcoma. Salarius Pharmaceuticals, Inc. has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds; HLB Life Sciences to develop, produce, manufacture, use, and sell the drug in South Korea; and Cancer Prevention and Research Institute of Texas for product development activities. The company is headquartered in Houston, Texas.

News

My Thoughts For You
We have retested resistance 3 times in overbought conditions. I suspect a retracement then a continuation towards resistance level 2, from here we will see a correction testing support and resistance in the form of a 3 wave ABC correction, I suspect that C wave will be 100% of wave A and that brings the price at support level 2.

Keep an eye on the current resistance because we may breakthrough to complete wave 5 then the ABC correction will follow, either way the price is going to be in a correction.

Good Luck, Cheers!

Be sure to comment, follow, like, and check out my profile for more trade ideas!


Disclaimer

The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.